Current knowledge about FLT3 gene mutations, exploring the isoforms, and protein importance in AML

Area of Science:

• Hematology
• Molecular Biology
• Oncology

Background:

• Acute myeloid leukaemia (AML) is a heterogeneous cancer driven by genetic mutations.
• FLT3 gene mutations are significant in AML pathogenesis, affecting prognosis.
• FLT3 protein's role in normal hematopoiesis and its dysregulation in AML are critical.

Purpose of the Study:

• To review current knowledge on FLT3 gene mutations and isoforms in AML.
• To explore the importance of FLT3 protein in AML development and progression.
• To discuss FLT3-targeted therapies and resistance mechanisms.

Main Methods:

• Literature review of FLT3 gene mutations (FLT3-ITD, FLT3-TKD) and isoforms in AML.
• Analysis of FLT3 signaling pathway activation and its impact on AML.
• Examination of FLT3-targeted therapies, including tyrosine kinase inhibitors.

Main Results:

• FLT3 mutations (FLT3-ITD, FLT3-TKD) occur in 25-30% of AML cases, correlating with poor prognosis.
• FLT3-ITD mutations cause constitutive pathway activation, enhancing cell survival and proliferation.
• FLT3 isoforms and polymorphisms may influence AML prognosis and treatment response.

Conclusions:

• FLT3 mutations are crucial drivers in AML, necessitating targeted therapeutic strategies.
• Development of FLT3 inhibitors offers new treatment avenues, but resistance remains a challenge.
• Further research into FLT3 biology, including domain rearrangements, is vital for advancing AML treatment.